205 related articles for article (PubMed ID: 32932591)
1. Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.
Novakova Z; Belousova N; Foss CA; Havlinova B; Gresova M; Das G; Lisok A; Prada A; Barinkova M; Hubalek M; Pomper MG; Barinka C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932591
[TBL] [Abstract][Full Text] [Related]
2. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
Nováková Z; Foss CA; Copeland BT; Morath V; Baranová P; Havlínová B; Skerra A; Pomper MG; Barinka C
Prostate; 2017 May; 77(7):749-764. PubMed ID: 28247415
[TBL] [Abstract][Full Text] [Related]
3. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
4. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS
Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
7. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.
Frigerio B; Benigni F; Luison E; Seregni E; Pascali C; Fracasso G; Morlino S; Valdagni R; Mezzanzanica D; Canevari S; Figini M
Immunol Lett; 2015 Nov; 168(1):105-10. PubMed ID: 26404855
[TBL] [Abstract][Full Text] [Related]
8. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
9. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
10. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
[TBL] [Abstract][Full Text] [Related]
12. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591.
Parker SA; Diaz IL; Anderson KA; Batt CA
Protein Expr Purif; 2013 Jun; 89(2):136-45. PubMed ID: 23500147
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
14. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
[TBL] [Abstract][Full Text] [Related]
15. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
16. Anti-PSMA
Frigerio B; Morlino S; Luison E; Seregni E; Lorenzoni A; Satta A; Valdagni R; Bogni A; Chiesa C; Mira M; Canevari S; Alessi A; Figini M
J Exp Clin Cancer Res; 2019 Jul; 38(1):326. PubMed ID: 31337429
[TBL] [Abstract][Full Text] [Related]
17. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
18. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
19. A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.
Nawaz S; Mullen GED; Blower PJ; Ballinger JR
Nucl Med Commun; 2017 Aug; 38(8):666-671. PubMed ID: 28598898
[TBL] [Abstract][Full Text] [Related]
20. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
